No Data
No Data
Is Zai Lab (NASDAQ:ZLAB) Using Too Much Debt?
Express News | Zai Lab Reports Topline Data From Phase 3 Bridging Trial Evaluating KarXT For Schizophrenia In China; KarXT Demonstrated A Statistically Significant 9.2-Point Reduction In PANSS Total Score From Baseline At Week 5 Compared To Placebo, Trial Met All...
Express News | Cantor Fitzgerald Reiterates Overweight on Zai Lab
Leerink Partners Maintains Zai Lab(ZLAB.US) With Buy Rating, Raises Target Price to $72
Analysts' Top Healthcare Picks: Universal Health (UHS), Zai Lab (ZLAB)
Zai Lab Limited (ZLAB) Moves 14.7% Higher: Will This Strength Last?